Sleep medicine · 2025
Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Wubing
Аннотация
BACKGROUND: Chronic insomnia (CI) commonly co-occurs with chronic migraine (CM), and neuroinflammation may underlie this association. Galectin-3, a pro-inflammatory mediator, has been implicated in migraine and sleep regulation, but its role in CM-related insomnia and its link to NLRP3 inflammasome activation remain unclear.
METHODS: We conducted a case-control study of 150 CM patients, categorized by CI status using ICSD-3 criteria and Pittsburgh Sleep Quality Index (PSQI). Clinical features, psychological assessments, and plasma biomarkers (Galectin-3, NLRP3, IL-1β) were measured. Logistic regression, multiple linear regression, mediation analysis, and ROC curves evaluated associations and diagnostic performance.
RESULTS: Compared with CM without insomnia (CM-nCI), CM with insomnia (CM-CI) showed higher Galectin-3 (18.69 ± 2.95 vs. 13.41 ± 2.48 ng/mL), NLRP3 (6.72 ± 1.24 vs. 4.02 ± 1.14 ng/mL), and IL-1β (5.39 ± 1.27 vs. 3.71 ± 0.87 pg/mL; all P < 0.001). Galectin-3 independently predicted CI (adjusted OR = 1.393; 95 % CI: 1.153-1.681; P < 0.001). Mediation analysis indicated partial mediation by NLRP3 and IL-1β (41.4 % and 36.2 %, respectively). ROC analysis demonstrated good discrimination (AUC = 0.888; cutoff = 15.85 ng/mL; sensitivity = 84.0 %; specificity = 82.0 %). Galectin-3 correlated with PSQI, anxiety, depression, migraine impact, and inflammatory markers after adjustment (all P < 0.001).
CONCLUSION: Elevated plasma Galectin-3 is strongly associated with CI in CM and shows good predictive value. Its relationship with NLRP3 and IL-1β suggests a shared neuroinflammatory pathway, highlighting Galectin-3 as a potential biomarker for risk stratification and targeted management of CM patients with insomnia.
METHODS: We conducted a case-control study of 150 CM patients, categorized by CI status using ICSD-3 criteria and Pittsburgh Sleep Quality Index (PSQI). Clinical features, psychological assessments, and plasma biomarkers (Galectin-3, NLRP3, IL-1β) were measured. Logistic regression, multiple linear regression, mediation analysis, and ROC curves evaluated associations and diagnostic performance.
RESULTS: Compared with CM without insomnia (CM-nCI), CM with insomnia (CM-CI) showed higher Galectin-3 (18.69 ± 2.95 vs. 13.41 ± 2.48 ng/mL), NLRP3 (6.72 ± 1.24 vs. 4.02 ± 1.14 ng/mL), and IL-1β (5.39 ± 1.27 vs. 3.71 ± 0.87 pg/mL; all P < 0.001). Galectin-3 independently predicted CI (adjusted OR = 1.393; 95 % CI: 1.153-1.681; P < 0.001). Mediation analysis indicated partial mediation by NLRP3 and IL-1β (41.4 % and 36.2 %, respectively). ROC analysis demonstrated good discrimination (AUC = 0.888; cutoff = 15.85 ng/mL; sensitivity = 84.0 %; specificity = 82.0 %). Galectin-3 correlated with PSQI, anxiety, depression, migraine impact, and inflammatory markers after adjustment (all P < 0.001).
CONCLUSION: Elevated plasma Galectin-3 is strongly associated with CI in CM and shows good predictive value. Its relationship with NLRP3 and IL-1β suggests a shared neuroinflammatory pathway, highlighting Galectin-3 as a potential biomarker for risk stratification and targeted management of CM patients with insomnia.